Pacer Advisors Inc. lifted its stake in Teleflex Incorporated (NYSE:TFX) by 21.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,013 shares of the medical technology company’s stock after acquiring an additional 884 shares during the quarter. Pacer Advisors Inc.’s holdings in Teleflex were worth $1,660,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Reilly Financial Advisors LLC acquired a new stake in shares of Teleflex during the 2nd quarter valued at about $25,000. Quantamental Technologies LLC bought a new stake in Teleflex in the first quarter worth $26,000. Quadrant Capital Group LLC boosted its holdings in Teleflex by 82.8% in the first quarter. Quadrant Capital Group LLC now owns 117 shares of the medical technology company’s stock worth $33,000 after purchasing an additional 53 shares in the last quarter. Icon Wealth Partners LLC acquired a new position in Teleflex during the first quarter worth $37,000. Finally, Cullen Frost Bankers Inc. acquired a new position in Teleflex during the second quarter worth $52,000. 90.67% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have weighed in on the company. Morgan Stanley boosted their price target on Teleflex from $345.00 to $392.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Needham & Company LLC reissued a “buy” rating and set a $403.00 price objective (up previously from $325.00) on shares of Teleflex in a report on Friday, August 2nd. Wells Fargo & Co initiated coverage on Teleflex in a report on Tuesday, June 11th. They set an “outperform” rating and a $345.00 price objective on the stock. Leerink Swann set a $405.00 price objective on Teleflex and gave the company a “buy” rating in a research note on Wednesday, September 4th. Finally, Zacks Investment Research lowered Teleflex from a “buy” rating to a “hold” rating in a report on Tuesday, May 14th. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Teleflex presently has an average rating of “Buy” and a consensus target price of $374.45.
Shares of NYSE TFX traded up $4.00 during midday trading on Wednesday, reaching $342.88. 77,643 shares of the company traded hands, compared to its average volume of 234,492. Teleflex Incorporated has a 12 month low of $226.02 and a 12 month high of $373.90. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.59 and a current ratio of 2.52. The stock’s 50-day simple moving average is $359.14 and its 200-day simple moving average is $318.55. The firm has a market cap of $15.80 billion, a PE ratio of 34.63, a PEG ratio of 2.21 and a beta of 1.00.
Teleflex (NYSE:TFX) last announced its earnings results on Thursday, August 1st. The medical technology company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.59 by $0.07. Teleflex had a return on equity of 18.57% and a net margin of 10.78%. The business had revenue of $652.50 million for the quarter, compared to the consensus estimate of $637.06 million. During the same period in the previous year, the business earned $2.47 EPS. Teleflex’s revenue was up 7.0% compared to the same quarter last year. On average, equities research analysts expect that Teleflex Incorporated will post 11.03 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Monday, September 16th. Investors of record on Thursday, August 15th will be given a dividend of $0.34 per share. The ex-dividend date of this dividend is Wednesday, August 14th. This represents a $1.36 annualized dividend and a yield of 0.40%. Teleflex’s dividend payout ratio (DPR) is 13.74%.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.
Featured Story: Certificate of Deposit (CD)
Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX).
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.